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OBJECTIVE
To investigate the efficacy and safety of liraglutide added to capped insulin doses
in subjects with type 1 diabetes.
RESEARCH DESIGN AND METHODS
A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling
835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8,
1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of
insulin.
RESULTS
Mean baseline glycated hemoglobin (HbA1c) (8.1% [65.0 mmol/mol]) was signif-
icantly decreased with liraglutide versus placebo at week 26 (1.8 mg: –0.33%
[3.6 mmol/mol]; 1.2mg: –0.22% [2.4 mmol/mol]; 0.6 mg: –0.23% [2.5 mmol/mol];
placebo: 0.01% [0.1 mmol/mol]). Liraglutide significantly reduced mean body
weight (–5.1, –4.0, and –2.5 kg for 1.8, 1.2, and 0.6 mg, respectively) versus
placebo (–0.2 kg). Significant reductions in daily insulin dose and increases in
quality of life were seen with liraglutide versus placebo. There were higher rates
of symptomatic hypoglycemia (21.3 vs. 16.6 events/patient/year; P = 0.03) with
liraglutide 1.2mg vs. placebo and of hyperglycemia with ketosis >1.5mmol/L with
liraglutide 1.8 mg vs. placebo (0.5 vs. 0.1 events/patient/year; P = 0.01).
CONCLUSIONS
In a broad population of subjects with long-standing type 1 diabetes, liraglutide
added to capped insulin reduced HbA1c, body weight, and insulin requirements
but with higher rates of hypoglycemia for liraglutide 1.2 mg and hyperglycemia
with ketosis for liraglutide 1.8 mg.
Most people with type 1 diabetes do not currently reach glycemic targets (1), as
both patients and providers are often reluctant to intensify glycemic therapy be-
cause of reasons such as concern about hypoglycemia and/or weight gain (2).
Moreover, a recent study using electronic health records from the U.S. reported
that 47.8% of people with type 1 diabetes are obese (3). Therefore, noninsulin
adjunctive treatments with a low intrinsic risk of hypoglycemia and weight gain
offer a potential means of complementing intensive insulin therapy in people
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with type 1 diabetes (4). However, the
evidence base for such treatments is
limited (5), and only pramlintide, an an-
alog of human amylin (6), is currently
approved by the U.S. Food and Drug Ad-
ministration for use with mealtime in-
sulin in people with type 1 diabetes (7).
In people with type 2 diabetes, lira-
glutide, a glucagon-like peptide-1 re-
ceptor agonist (GLP-1RA), is known to
stimulate insulin secretion, improve
b-cell function, and inhibit glucagon re-
lease froma-cells in a glucose-dependent
manner (8). Furthermore, liraglutide de-
creases food intake (9) and has weight
loss benefits in type 2 diabetes (10–14).
Whether similar responses exist in people
with type 1 diabetes is uncertain. Small,
nonrandomized studies in subjects with
type 1 diabetes suggest that GLP-1RA
treatment results in reduction in fasting
and postprandial hyperglycemia, post-
prandial glucagon plasma levels, glucose
excursions, hypoglycemic events, insulin
requirements, and body weight, but these
results have not yet been confirmed
in larger studies with longer duration
(15–23). Recently, two such randomized
controlled trials (RCTs) investigating the
efficacy and safety of liraglutide added
to insulin in subjects with type 1 diabetes
have been completed (ADJUNCT ONE
[NCT01836523] [24] and ADJUNCT TWO
[NCT02098395]). Here we report findings
from the ADJUNCT TWO trial.
The primary aim of ADJUNCT TWO
was to confirm, in a large, multicenter,
randomized study, superiority of lira-
glutide compared with placebo, both
adjunct to capped insulin treatment,
on glycemic control, after 26 weeks of
treatment in subjects with established
type 1 diabetes and inadequate glycemic
control.
RESEARCH DESIGN AND METHODS
Trial Design
This was a 26-week, randomized, insulin-
capped, placebo-controlled, double-blind,
parallel-group, phase 3 trial performed at
59 centers in North America, Europe, and
Africa.
After a screening visit (week –2), eligible
subjects attended the randomization visit
(week 0) and were randomized using a
telephone or web-based system (IV/WRS)
by Novo Nordisk (Clinical Supplies Coordi-
nation) (stratified by glycated hemoglobin
[HbA1c] [,8.5%; ,69.4 mmol/mol and
$8.5%; $69.4 mmol/mol] and BMI
[#27 and .27 kg/m2]). Subjects were
randomized 3:1 to liraglutide 1.8, 1.2,
and 0.6 mg, or liraglutide placebo 0.3,
0.2, or 0.1 mL, respectively, as adjunct
to insulin treatment for a period of
26 weeks. Treatment with liraglutide
(or the corresponding placebo volume)
was started at 0.6 mg/day at week 0 and
increased by 0.6 mg every 2nd week un-
til the randomized dose level was
reached. In order to obtain a dose re-
sponse, dose reduction of liraglutide
was not permitted on randomized dose.
To ensure treatment uniformity be-
tween the trial sites, as well as to ensure
that subjects received treatment ac-
cording to the trial protocol, titration
algorithms were developed specifying
recommended insulin dose adjustments
at different plasma glucose levels. Sub-
jects were instructed to perform self-
monitoring of plasma glucose (SMPG)
(4-, 7-, and 9-point profiles) on days be-
fore site and phone contacts and after
new liraglutide dose escalation. The in-
sulin cap was determined for each sub-
ject individually prior to randomization
and, as it is acknowledged that people
with type 1 diabetes can have large fluc-
tuations in insulin dose on a daily basis,
was defined as the average of the pre-
vious 7 consecutive days’ total daily in-
sulin dose. No range limit or lower limit
for insulin requirement was set. No
postprandial glucose targets were set.
However, adjustments based on post-
prandial glucose within the limits of
the insulin cap were at the discretion
of the investigator in accordance with
local practice/standard of medical care.
The total daily prerandomization insu-
lin dose was reduced by 25% for at
least 1 day when liraglutide or placebo
was initiated, and by a further 10% for
at least 1 day when liraglutide/placebo
doses were escalated. Thereafter, the
insulin dose could be adjusted weekly
by subjects and at least biweekly by
investigators, based on 4-point glucose
(premeal) values, toward the insulin
cap as defined previously. In case of se-
vere deterioration of glycemic control,
rescue treatment was to be initiated
(Supplementary Fig. 1).
Trial Population
Key inclusion criteria comprised the fol-
lowing: type 1 diabetes duration $1
year, age $18 years, BMI $20 kg/m2,
treatment with multiple daily injections
(MDI) of insulin or continuous subcuta-
neous insulin infusion (CSII) for at least
6 months, and HbA1c 7.0–10.0% (53.0–
85.8 mmol/mol) with a stable insulin
dose (as judged and documented by
the investigator) for at least 3 months.
In order to increase applicability of re-
sults to clinical practice, “fragile” sub-
jects (i.e., subjects with hypoglycemic
unawareness, history of severe hypogly-
cemia, mildly to severely decreased re-
nal function [based on chronic kidney
disease definitions] [25], or a recent his-
tory of diabetic ketoacidosis) were not
excluded. Key exclusion criteria com-
prised the following: any prior use of
GLP-1RAs or dipeptidyl peptidase-4 in-
hibitors, any medication (except insulin)
that could interfere with glycemic con-
trol or affect a subject’s safety, or an
estimated glomerular filtration rate
,30 mL/min/1.73 m2.
Outcome Measures
The primary end point was change from
baseline in HbA1c after 26 weeks of treat-
ment. Secondary end points included
change from baseline in body weight, to-
tal daily insulin dose, 1,5-anhydroglucitol,
fasting plasma glucose, 9-point SMPG
(using a self-measured blood glucose
device calibrated to report plasma glu-
cose), fasting plasma glucagon, plasma
C-peptide, and quality of life (treatment-
related impact measures-diabetes
[TRIM-D], TRIM-hypoglycemia [TRIM-
HYPO], and short-form 36 question-
naires) and proportions of subjects
achieving HbA1c targets (HbA1c ,7.0%
[,53.0 mmol/mol]; composite targets
[HbA1c ,7.0% (,53.0 mmol/mol) and no
severe hypoglycemia; HbA1c reduction
.1% (.10.9mmol/mol) and no severe hy-
poglycemia]) after 26 weeks of treatment.
Safety end points included incidence
of symptomatic hypoglycemic episodes,
defined as severe according to the
American Diabetes Association (ADA)
(26) or by a plasma glucose value of
,3.1 mmol/L (,56 mg/dL) with symp-
toms consistent with hypoglycemia
(Novo Nordisk definition). Furthermore,
documented symptomatic, asymptomatic,
severe, and nocturnal (12:01205:59 A.M.,
both inclusive) hypoglycemic episodes
were reported (26). Asymptomatic hy-
poglycemic episodes according to the
Novo Nordisk definition (plasma glu-
cose ,3.1 mmol/L [,56 mg/dL] and
no symptoms) were investigated as a
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post hoc end point. Hyperglycemic epi-
sodes (plasma glucose .16.7 mmol/L
[.300 mg/dL]), hyperglycemic epi-
sodes with ketosis (plasma ketone
.1.5 mmol/L [based on vendor’s user
recommendations for the ketostick]),
and adverse events (AEs) were also re-
ported. Subjects were advised to mea-
sure ketones at each plasma glucose
excursion.16.7 mmol/L (.300 mg/dL).
Subgroup Analyses
Analyses were performed to identify po-
tential subgroups of subjects with an
improved treatment effect. Prespecified
analyses included baseline variables
such as age, sex, type 1 diabetes dura-
tion, method of insulin administration
(MDI versus CSII), body weight, BMI,
HbA1c, hypoglycemia unawareness sta-
tus, and severe hypoglycemia within the
last 12 months. No subgroup analysis
was performed related to the prandial
insulin-adjusting algorithm, as it was
based on clinical judgement. Post hoc
analyses included baseline variables
such as C-peptide level.
Statistical Analyses
Sample size was determined to detect a
difference of 0.4% (4.4 mmol/mol) in
HbA1c change and 2.5 kg in body weight
change after 26 weeks of treatment be-
tween the liraglutide 1.8 mg dose and
placebo with 90.0 and 99.9% power, re-
spectively. Sample size calculation was
based on a two-sided Student t test of
5% and an SD of 1.1% (12.0 mmol/mol)
in HbA1c change after 26 weeks of treat-
ment. The required sample size was
160 subjects per group, assuming no pa-
tients withdrew. Adopting an overall
20% dropout rate evenly distributed
among treatment groups, the required
sample size was 200 subjects per group.
With a 50% efficacy retention in the
dropouts, a treatment difference of
0.36% was then expected.
Continuous data were analyzed us-
ing a mixed model for repeated mea-
surements, with treatment, stratification,
and country as fixed factors and baseline
as a covariate, all nested within visit.
Binary data were analyzed by a logistic
regression model, with treatment and
stratification as factors and HbA1c value
at baseline as a covariate. Missing
HbA1c data were imputed from the
mixed model for repeated measure-
ments used for the analysis of HbA1c.
Numbers of on-treatment hypoglycemic/
hyperglycemic episodes were analyzed
using a negative binomial regression
model, with a log-link function and the
logarithm of the time period in which the
episodes were considered treatment
emergent as offset, with treatment, strat-
ification, and country as factors and the
HbA1c value at baseline as a covariate.
RESULTS
Subject Disposition
Of the 835 randomized subjects, 832
were exposed to liraglutide or placebo
in addition to insulin during the trial
(liraglutide 0.6 mg, n = 211; 1.2 mg,
n = 209; 1.8 mg, n = 206; placebo, n =
206) and 661 subjects completed week
26 without discontinuation of trial
product or use of rescue treatment (in-
tensification of usual insulin dose) (lira-
glutide 0.6 mg, n = 177; 1.2 mg, n = 157;
1.8 mg, n = 157; placebo, n = 170) (Sup-
plementary Fig. 1). Overall, rescue treat-
ment was needed in 42 (5.0%) subjects.
More subjects in the liraglutide 1.2 mg
group required rescue treatment (n =
16, 7.7%) than in the other treatment
groups (liraglutide 1.8 mg: n = 8, 3.9%;
0.6 mg: n = 9, 4.2%; placebo: n = 9,
4.3%). In total, 127 (15.2%) subjects with-
drew from the trial: n = 42 (20.3%), n =
32 (15.3%), n = 26 (12.3%), and n =
27 (13.0%) in the liraglutide 1.8, 1.2, and
0.6 mg and placebo groups, respectively.
Baseline Characteristics
On average, the trial population had
longstanding (mean duration 21.1
years) type 1 diabetes with inadequate
glycemic control (mean HbA1c 8.1%
[65.0 mmol/mol]) and was moderately
overweight (mean body weight 83.9 kg;
mean BMI 28.9 kg/m2) (Table 1). In to-
tal, 125 (15.2%) subjects had C-peptide
levels greater than the lower limit of
quantification (.LLOQ: 0.030 nmol/L)
(Supplementary Table 1) and 213 (25.6%)
subjects were receiving CSII. Overall,
mean (geometric) total daily insulin
dose was 10.0 units higher in subjects
receiving MDI of insulin than in subjects
receiving CSII. Almost half of the sub-
jects had some symptoms or diagnosis
of long-term diabetes complications,
47 (5.7%) subjects had hypoglycemia un-
awareness, and 61 (7.3%) had a history of
severe hypoglycemia.
Efficacy
HbA1c reductions occurred in the first
3 months of the trial, after which HbA1c
levels increased gradually. From base-
line to week 26, HbA1c was large-
ly unchanged with placebo (0.01%
[0.1 mmol/mol]), whereas a statistically
significant reduction in HbA1c was seen
for all liraglutide doses versus placebo
(estimated treatment difference [ETD]:
1.8 mg, –0.35%/–3.8 mmol/mol [95% CI
–0.50; –0.20], P , 0.0001; 1.2 mg,
–0.23%/–2.5 mmol/mol [95% CI –0.38;
–0.08], P = 0.0021; 0.6 mg, –0.24%/
–2.6 mmol/mol [95% CI –0.39; –0.10],
P = 0.0011) (Fig. 1A). The reduction in
HbA1c reported with liraglutide 1.8 mg
was accompaniedby a significantly greater
increase in mean 1,5-anhydroglucitol
compared with placebo (end-of-trial val-
ues: 3.11 mg/mL and 2.68 mg/mL, re-
spectively; estimated treatment ratio:
1.16 [95% CI 1.05; 1.28], P = 0.0026)
and, with the 9-point SMPG profiles,
apparent reductions in postbreak-
fast, postlunch, and bedtime glucose
(Supplementary Fig. 2). With liraglutide
1.2 and 0.6 mg, there was no significant
effect (compared with placebo) on 1,5-
anhydroglucitol and no apparent reduc-
tions in 9-point SMPG profiles. There
were no significant differences between
any of the liraglutide doses and placebo
for mean fasting plasma glucose, mean
fasting plasma glucagon, or mean plasma
C-peptide at 26 weeks.
A significant dose-dependent de-
crease in mean (geometric) total daily
insulin dose was reported with all lira-
glutide doses at 26 weeks compared
with placebo (estimated treatment ra-
tio: 1.8 mg, 0.90 [95% CI 0.86; 0.93],
P , 0.0001; 1.2 mg, 0.93 [95% CI 0.90;
0.96], P , 0.0001; 0.6 mg, 0.95 [95% CI
0.92; 0.99], P = 0.0075) (Fig. 1B). This
insulin dose reduction in the liraglutide
groups was achieved mainly through a
prandial insulin reduction. Themean de-
crease of prandial insulin was –4 to –5
units and –3 to –5.5 units in subjects
receivingMDI of insulin and CSII, respec-
tively, whereas the dose decrease in
basal insulin was –0.9 to 0.2 units and
–0.1 to –0.9 units, respectively.
A dose-dependent statistically signif-
icant decrease in mean body weight
from baseline to week 26 was reported
with liraglutide (1.8 mg, –5.1 kg; 1.2 mg,
–4.0 kg; 0.6 mg, –2.5 kg; placebo,
–0.2 kg, all P , 0.0001) (Fig. 1C).
At 26 weeks, significantly more sub-
jects receiving liraglutide 1.8 mg com-
pared with placebo achieved the ADA
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target of HbA1c,7.0% (,53.0mmol/mol)
(18.8 vs. 10.0%, respectively, odds ra-
tio [OR] 2.12 [95% CI 1.11; 4.06], P =
0.0231) (Fig. 2A). There was no signifi-
cant effect of liraglutide 1.2 and 0.6 mg
compared with placebo on this end
point. Significantly more subjects re-
ceiving liraglutide 1.8 mg (but not those
receiving liraglutide 1.2 or 0.6 mg) ver-
sus placebo achieved the composite
target ofHbA1c,7.0% (,53.0mmol/mol)
with no severe hypoglycemia (18.2 vs.
10.0%, respectively, OR 2.02 [95% CI
1.05; 3.87], P = 0.0343) (Fig. 2B). Similarly,
significantly more subjects receiving liraglu-
tide 1.8 mg (15.3%), 1.2 mg (11.3%), and
0.6 mg (11.1%) versus placebo (3.7%)
achieved the composite target of HbA1c
reduction .1.0% (.10.9 mmol/mol) and
no severe hypoglycemia (1.8 mg: OR 5.36
[95% CI 2.21; 12.96], P = 0.0002;
1.2 mg: OR 3.48 [95% CI 1.41; 8.59],
P = 0.0069; 0.6 mg: OR 3.39 [95%
CI 1.38; 8.34], P = 0.0078) (Fig. 2C).
Safety
Overall, rates of AEs increased with
liraglutide in a dose-dependent manner
(11.5, 9.6, and 7.0 events per patient
year of exposure [PYE] for liraglutide
1.8, 1.2, and 0.6 mg, respectively, com-
pared with 6.3 events per PYE for pla-
cebo) (Table 2). However, there was a
similar proportion of subjects with seri-
ous AEs across the treatment groups
(6.8, 10.0, and 9.5% for liraglutide 1.8,
1.2, and 0.6 mg, respectively, compared
with 6.8% for placebo). There was a
higher rate of study discontinuation
due to AEs in the liraglutide group
than in the placebo group. Nausea,
which increased dose dependently
(2.0, 1.3, and 0.8 events per PYE for lira-
glutide 1.8, 1.2, and 0.6 mg, respec-
tively, and 0.4 events per PYE for
placebo), was the most frequently re-
ported AE with liraglutide. In all liraglu-
tide groups, new-onset nausea tended
to occur within the first weeks of treat-
ment (i.e., during dose initiation and
escalation); after this time, the inci-
dence of nausea decreased.
Throughout the trial, there were
four adjudicated cardiovascular events
(three acute coronary syndromes [one
with liraglutide 0.6 mg, one with liraglu-
tide 1.2 mg, and one with placebo] and
one cerebrovascular event [liraglutide
1.8 mg]), four neoplasms (three benign
[liraglutide 1.8 mg, liraglutide 1.2 mg,
and placebo] and one malignant [lira-
glutide 1.8 mg]), and one thyroid event
requiring thyroidectomy (C-cell hyper-
plasia [liraglutide 1.8mg]) (Supplementary
Material). There was no apparent pattern
with regards to treatment dose of lira-
glutide. There was a single confirmed
case of diabetic ketoacidosis requiring
hospitalization with liraglutide 1.2 mg
(in a subject who was not compliant
with treatment algorithms) and no fatal
events in any treatment group. Mean li-
pase and amylase levels increased sig-
nificantly in all liraglutide treatment
groups (Supplementary Table 2). How-
ever, the majority of subjects in each
treatment group had postbaseline lipase
and amylase values within the normal
range. There were transient elevations
of lipase greater than three times the up-
per limit of normal in all liraglutide groups
(1.8 mg, n = 4 [1.9%]; 1.2 mg, n = 4 [1.9%];
0.6 mg, n = 2 [1.0%]). One subject in the
placebo group had a transient elevation
of amylase greater than three times the
upper limit of normal. No cases of pancre-
atitis were reported in any treatment
Table 1—Demographics and baseline characteristics
Liraglutide 1.8 mg
(n = 205)
Liraglutide 1.2 mg
(n = 209)
Liraglutide 0.6 mg
(n = 211)
Placebo
(n = 206)
Age (years)† 43.2 (18; 75) 42.8 (18; 73) 43.9 (19; 87) 42.7 (18; 70)
Female:male (%) 55:45 51:49 56:44 54:46
Duration of type1 diabetes (years)† 21.4 (1; 53) 21.1 (1; 52) 21.0 (1; 58) 20.7 (1; 54)
MDI* (%) 75 (67/33) 73 (70/30) 75 (66/34) 75 (62/38)
Total insulin dose 58.4 58.8 58.8 61.7
MDI (units/day) (geometric mean)
CSII (%) 25 27 25 25
Total insulin dose 50.1 46.8 47.9 50.3
CSII (units/day) (geometric mean)
Hypoglycemic unawareness (yes/no) (%) 5/95 7/93 8/92 3/97
Severe hypoglycemia within last year (0/.1) (%) 93/7 91/9 92/8 95/5
Body weight (kg) 83.6 84.7 83.1 84.2
BMI (kg/m2) 28.9 28.8 28.9 28.9
HbA1c (%) 8.04 8.07 8.09 8.12
HbA1c (mmol/mol) 64.4 64.7 64.9 65.2
Fasting plasma C-peptide (nmol/L) 0.037 0.031 0.052 0.033
,LLOQ (%) 84 84 83 89
$LLOQ (%) 16 16 17 11
eGFR (mL/min/1.73 m2) 94 94 94 97
Diabetic retinopathy (%) 38 29 37 35
Diabetic neuropathy (%) 21 20 27 22
Diabetic nephropathy (%) 9 3 11 12
Diabetic macroangiopathy (%) 3 1 3 4
Hypertension (%) 31 38 37 38
eGFR, estimated glomerular filtration rate. *(Basal once daily/$b.i.d.); †(Min; Max).
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group. There was no apparent differ-
ence between the treatment groups in
the proportion of subjects who had cal-
citonin categorized as either ,LLOQ
or $LLOQ at weeks –2 and 26 as well
as for median, minimum, and maximum
values (Supplementary Table 2). Mean
pulse and systolic blood pressure signif-
icantly increased and decreased, re-
spectively, in all liraglutide treatment
groups (Supplementary Table 2). There
was no significant effect on mean dia-
stolic blood pressure.
Hypoglycemic Episodes
In total, 92–98% of subjects reported at
least one hypoglycemic episode during
the trial, and hypoglycemic episodes
were uniformly distributed throughout
the trial period. For most hypoglycemia
end points, the number of episodes was
similar across treatment groups (Table
2). There was a higher rate of symp-
tomatic (estimated rate ratio [ERR]
1.31 [95% CI 1.03; 1.68], P = 0.0289)
and documented symptomatic (ERR
1.33 [95% CI 1.07; 1.67], P = 0.0114)
hypoglycemic episodes only with lira-
glutide 1.2 mg compared with placebo
(21.3 vs. 16.6 events per PYE and 42.4
vs. 33.6 events per PYE, respectively). For
all liraglutide doses, there was no signifi-
cant difference in rate of severe or noc-
turnal hypoglycemic episodes compared
with placebo. Rates of asymptomatic
hypoglycemic episodes, with plasma
glucose ,3.1 mmol/L (,56 mg/dL)
(Novo Nordisk definition), were 4.9,
4.4, 4.8, or 5.5 events per PYE on liraglu-
tide 1.8, 1.2, or 0.6 mg or placebo, re-
spectively. Rates of asymptomatic
hypoglycemic episodes, with plasma
glucose ,3.9 mmol/L (,70 mg/dL),
were also similar between treatment
groups (Table 2).
Hyperglycemic Episodes
Overall, there were no differences in
the rates of hyperglycemic episodes with
liraglutide compared with placebo (40.5,
44.8, and 40.0 events per PYE for liraglu-
tide 1.8, 1.2, and 0.6 mg, respectively,
compared with 45.7 events per PYE for
placebo). Hyperglycemic episodes were
uniformly distributed throughout the
trial period. There was a higher rate of
hyperglycemic episodes with ketosis
.1.5 mmol/L with liraglutide 1.8 mg
compared with placebo (42 events in
17 subjects and 10 events in 9 subjects
[0.5 vs. 0.1 events per PYE], respectively,
ERR 3.96 [95% CI 1.49; 10.55], P =
0.0059). There were higher rates of hy-
perglycemic episodes with ketosis re-
ported with liraglutide 1.2 and 0.6 mg
compared with placebo (20 events in
13 subjects and 23 events in 17 subjects
[0.2 and 0.2 vs. 0.1 events per PYE], re-
spectively); however, these differences
were not statistically significant. Hyper-
glycemic episodes with ketosis occurred
more frequently in the first 8 weeks of
the trial.
Subgroup Analyses
With theexceptionofC-peptide–positive/–
negative subjects, the analyses of the
previously mentioned subgroups showed
comparable findings to the overall re-
sults. In the current trial, ;15% of sub-
jects (n = 125) had C-peptide levels
above the LLOQ, ranging between 0.08
and 0.12 nmol/L. These subjects also
differed from the overall population
by a slightly higher baseline HbA1c and
shorter type 1 diabetes duration
(Supplementary Table 1). These subjects
showed an improved treatment effect
Figure 1—A: Mean change in HbA1c by treatment week. B: Mean change in total insulin dose by
treatment week. C: Mean change in body weight by treatment week. Error bars are SEM. BL,
baseline; Lira, liraglutide.
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on HbA1c with all liraglutide doses
(1.8 mg: estimated mean placebo-
corrected HbA1c reduction of –0.77%
[–8.4 mmol/mol] compared with
–0.27% [–3.0 mmol/mol] for subjects
without measurable C-peptide, treat-
ment interaction P = 0.0302; 1.2 mg:
–0.69% [–7.5 mmol/mol] and –0.14%
[–1.6 mmol/mol], respectively, P =
0.0140; 0.6 mg: –0.65% [–7.1 mmol/mol]
and –0.17% [–1.9 mmol/mol], respec-
tively, P = 0.0293). Of note, of all
episodes of hyperglycemia with ketosis
.1.5 mmol/L (42, 20, 23, and 10 episodes
in the liraglutide 1.8, 1.2, and 0.6 mg and
placebo groups, respectively), only one
episode occurred in a subject with
measurable residual C-peptide (in the
liraglutide 0.6 mg group). Regarding
symptomatic hypoglycemia, there were
more episodes with liraglutide 1.2 mg
only compared with placebo in both the
baseline C-peptide groups ($LLOQ 8.5,
14.0, 10.6, and 7.4 events per PYE and
,LLOQ 19.2, 22.6, 16.1, and 17.8 events
per PYE for liraglutide 1.8, 1.2, and 0.6mg
and placebo, respectively).
Quality of Life
Mean TRIM-D management score was
reduced from baseline with placebo
(–1.48), which reflects a reduced quality
of life. However, with all liraglutide
doses, mean TRIM-Dmanagement score
was increased from baseline (1.8 mg:
7.46, 1.2 mg: 4.15, and 0.6 mg: 3.55),
reflecting improved quality of life. In-
creases in TRIM-D management score
were significantly greater with all liraglu-
tide doses than with placebo (1.8 mg:
ETD 8.94 [95% CI 4.33; 13.55], P =
0.0002; 1.2 mg: ETD 5.64 [1.01; 10.26],
P = 0.0170; 0.6 mg: ETD 5.04 [0.54; 9.54],
P = 0.0282), reflecting improved quality
of life. At 26 weeks and compared with
placebo, an increase in mean TRIM-D to-
tal score (driven by the corresponding
increase in mean TRIM-D management
score) was reported with liraglutide
1.8 mg (3.42 vs. 5.93, respectively, ETD
2.51 [95% CI 0.29; 4.73], P = 0.0269).
There was no significant effect of liraglu-
tide 1.2 and 0.6 mg on TRIM-D total
score compared with placebo. There
was no overall effect of any dose of
liraglutide on TRIM-HYPO total three do-
mains score or short-form 36 overall
physical or mental scores compared
with placebo.
CONCLUSIONS
ADJUNCT TWO is the first large-scale
RCT designed to investigate the efficacy
and safety of adding liraglutide to an
individually capped insulin dose in sub-
jects with type 1 diabetes and inade-
quate glycemic control. The current
trial demonstrates that liraglutide (1.8,
1.2, and 0.6mg) added to capped insulin
treatment results in greater mean reduc-
tions in HbA1c, body weight, and insulin
dose but higher rates of hypoglycemia
(1.2 mg) and hyperglycemia with keto-
sis (1.8 mg) compared with placebo.
These findings are largely in agree-
ment with those from ADJUNCT ONE, a
52-week randomized, placebo-controlled,
double-blind, parallel-group, treat-to-target,
Figure 2—Subjects achieving targets at week 26. A: HbA1c ,7.0% (,53.0 mmol/mol). B:
HbA1c ,7.0% (,53.0 mmol/mol) and no severe hypoglycemia. C: HbA1c reduction .1%
(.10.9 mmol/mol) and no severe hypoglycemia. *P , 0.05.
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phase 3 trial carried out at 177 centers
in 17 countries (24).
Considering efficacy, the mean re-
duction in HbA1c reported with liraglu-
tide 1.8 mg in the current trial was
modest (despite the greatest decrease
in pretrial insulin) but comparable to
that achieved with pramlintide (–0.5%
[–5.5 mmol/mol]) (27). Subgroup anal-
ysis in the current study indicates that in
C-peptide–positive subjects, the mean
placebo-corrected reduction in HbA1c
with liraglutide 1.8 mg is significantly
greater than in C-peptide–negative sub-
jects (i.e., –0.8 vs. –0.3%). In the overall
analysis, with liraglutide 1.8mg, therewas
an increase in mean 1,5-anhydroglucitol
as well as nonsignificant (compared with
placebo) reductions in postbreakfast,
postlunch, and bedtime SMPG measure-
ments that, together, suggest improve-
ments in both overall and postprandial
glycemic control. HbA1c reductions
that occurred were more pronounced
within the first 3 months of the trial,
after which HbA1c levels steadily in-
creased toward placebo levels. This sug-
gests that insulin dose increases could
have been more aggressive. Whether
expected insulin-associated weight
gain could have impacted the decision
to intensify insulin treatment fur-
ther throughout the trial remains
speculative.
In the current trial, the insulin capwas
imposed to reflect the added effect on
glycemic control in people who, in clin-
ical practice, may be reluctant to inten-
sify insulin treatment. Despite the HbA1c
reduction obtained, the mean total
daily insulin dose did not return to the
mean cap, and mean total daily insulin
doses were ;10–15% below baseline
values at week 26. It is noteworthy
that most, if not all, of the reduction
in total daily insulin dose was due
to prandial insulin. A recent study re-
ports a reduction in carbohydrate
intake, associated with appetite sup-
pression, and a reduction in postprandial
glucagon in subjects with type 1 dia-
betes being treated with liraglutide
(28). It could, therefore, be speculated
that in the current study, liraglutide
may have inhibited energy intake and
postprandial glucagon secretion, there-
by limiting the exogenous insulin re-
quirement. However, in ADJUNCT
TWO, neither possibility was specifically
investigated.
Weight loss and improvements in qual-
ity of life were additional benefits of lira-
glutide treatment in the current trial.
Liraglutide 1.8 mg resulted in a mean
reduction in body weight of –5.1 kg,
and this is comparable with findings
from a recent RCT involving a popula-
tion with type 1 diabetes and obesity
(–6.8 kg) (22). Intensive insulin treat-
ment in people with type 1 diabetes is
often associated with an increased
prevalence of overweight and obesity
over time (29). In the DCCT study after
6 years of treatment, for example, 4.75
kg more weight gain than convention-
ally treated counterparts was observed
(30). Furthermore, both overweight and
obesity are associated with insulin resis-
tance, dyslipidemia, increased blood pres-
sure, and atherosclerosis in a population
with type 1 diabetes (31). The improve-
ment in quality of life as evidenced by
the increased mean TRIM-D total score
and the mean TRIM-D management score
suggests that adjunctive liraglutide treat-
mentmay improve adherencewith poten-
tial longer-term benefits (32–34).
Table 2—Safety end points: on-treatment summary
Liraglutide 1.8 mg (n = 206) Liraglutide 1.2 mg (n = 209) Liraglutide 0.6 mg (n = 211) Placebo (n = 206)
n % R n % R n % R n % R
AEs
All AEs 180 87.4 11.5 184 88.0 9.6 173 82.0 7.0 160 77.7 6.3
Serious 14 6.8 0.2 21 10.0 0.3 20 9.5 0.3 14 6.8 0.2
Leading to discontinuation 33 16.0 0.7 20 9.6 0.4 12 5.7 0.3 2 1.0 0.0
Nausea 102 49.5 2.0 98 46.9 1.3 68 32.2 0.8 34 16.5 0.4
Vomiting 35 17.0 0.8 30 14.4 0.5 19 9.0 0.3 8 3.9 0.1
Diarrhea 30 14.6 0.5 27 12.9 0.4 14 6.6 0.2 17 8.3 0.2
Decreased appetite 50 24.3 0.6 40 19.1 0.5 21 10.0 0.2 9 4.4 0.1
Hypoglycemia
All episodes 201 97.6 54.1 204 97.6 58.7 200 94.8 47.9 189 91.7 50.6
Symptomatic* 160 77.7 17.4 175 83.7 21.3 166 78.7 15.0 162 78.6 16.6
Severe or BG confirmed* 179 86.9 22.3 185 88.5 25.7 177 83.9 19.8 169 82.0 22.1
Documented symptomatic 187 90.8 36.8 189 90.4 42.4 184 87.2 31.5 178 86.4 33.6
Asymptomatic 163 79.1 16.6 172 82.3 15.6 153 72.5 15.7 151 73.3 16.5
Severe 5 2.4 0.1 13 6.2 0.2 15 7.1 0.2 10 4.9 0.1
Nocturnal 124 60.2 6.0 127 60.8 6.4 126 59.7 5.5 124 60.2 6.0
Hyperglycemia
All episodes 175 85.0 40.5 188 90.0 44.8 185 87.7 40.0 191 92.7 45.7
Symptomatic 130 63.1 14.7 137 65.6 19.9 130 61.6 18.0 134 65.0 18.6
With ketosis 17 8.3 0.5 13 6.2 0.2 17 8.1 0.2 9 4.4 0.1
Symptomatic with ketosis 15 7.3 0.2 12 5.7 0.2 10 4.7 0.1 4 1.9 0.0
Symptomatic, severe according to the ADA classification (25) or a plasma glucose value of ,3.1 mmol/L (,56 mg/dL), with symptoms consistent
with hypoglycemia; severe or BG confirmed, hypoglycemic episodes that are either severe according to ADA or a plasma BG value of,3.1 mmol/L
(,56 mg/dL); documented symptomatic, typical symptoms of hypoglycemia accompanied by a measured plasma glucose concentration
#3.9 mmol/L (#70 mg/dL); asymptomatic, no typical symptoms of hypoglycemia, but with a measured plasma glucose concentration#3.9 mmol/L
(#70 mg/dL); severe, see symptomatic; nocturnal, onset was between 12:01 and 05.59 A.M., both included; hyperglycemia, plasma glucose
values.16.7mmol/L (.300mg/dL); ketosis, plasma ketone values.1.5mmol/L. BG, blood glucose; n, number of subjects experiencing at least one
event; R, event rate per PYE; %, percentage of subjects experiencing at least one event. *Novo Nordisk definition.
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Considering safety, higher numbers
of symptomatic hypoglycemia were
seen with liraglutide (1.2 mg) than
with placebo (21.3 vs. 16.6 events per
PYE, respectively). An explanation as to
why only one of the liraglutide doses
showed higher rates remains unclear.
It has been considered that this may re-
late to the insulin dose titration, nausea,
satiety, or misjudged food intake. How-
ever, currently no specific reason is di-
rectly supported by collected data.
Whether this is an intrinsic problem
with the use of GLP-1RAs in type 1 di-
abetes or if it could be mitigated by
patient selection, dosing, continuous
glucose monitoring, or education re-
mains speculative. It is of note that
liraglutide added to insulin treatment
does not affect the counter-regulatory
hormone responses during hypoglyce-
mia or glycemic recovery from hypogly-
cemia in subjects with type 1 diabetes
(21,35); consequently, the higher inci-
dence of hypoglycemia with liraglutide
is probably not dependent on defective
counter-regulation. Increased hypergly-
cemia with ketosis was also observed
with liraglutide compared with placebo.
In the liraglutide group, the reduction in
daily total insulin dosemay have contrib-
uted to this observation. Interestingly,
whereas there were .80 events of hy-
perglycemia with ketosis in the
C-peptide–negative population on lira-
glutide, there was only one event in the
C-peptide–positive population. The in-
creases in mean amylase, lipase, and
pulse and reductions in mean systolic
blood pressure reported in the liraglutide
groups are of unknown clinical signifi-
cance. Furthermore, these observations are
similar to those seen in type 2 diabetes–
focused trials involving this drug class
(36–38).
Considering trial limitations, the re-
sults may have benefited from the as-
sessment of food intake; moreover,
the use of continuous glucose monitor-
ing, absent from this trial, would have
gathered more comprehensive data on
glycemic variability, postprandial excur-
sions, and time in glycemic objectives.
The lack of standardization between
test centers in insulin titration methodol-
ogy could also be considered a limitation.
Furthermore, the capped insulin dose is
rarely used in clinical trials in subjects
with type 1 diabetes, making compari-
sons with other trials a challenge.
In summary, the ADJUNCT TWO trial
demonstrated benefits of liraglutide as
an adjunct to insulin treatment in sub-
jects with type 1 diabetes with a capped
insulin dose with respect to glycemic
control, insulin dose, weight, and qual-
ity of life. The higher number of hypo-
glycemia and of hyperglycemia with
ketosis in some of the liraglutide groups
emphasizes the need for proper insulin
titration and may ultimately limit the
clinical utility of GLP-1RAs in a less
well-supervised population with type 1
diabetes.
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